![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 12, 2021 5:40:06 PM
You could see something like that happening with us to get the stock price out of the $5s.....leak of a potential deal....I imagine we would start moving up quickly.
Inside the deal: As leaked details goosed its stock, Acceleron's CEO pumped Merck for more cash
Kyle Blankenship
Managing Editor
As leaked details of its potential merger with Merck were splashed across the internet, Acceleron behind the scenes used newfound interest from investors and a last-minute Hail Mary from an unnamed suitor to ply the drug giant for an even more pricey buyout, according to a play-by-play of the deal in an SEC filing.
After weeks of negotiation, Merck late last month agreed to acquire Acceleron and its lead rare cardiovascular disease drug sotatercept for $11.5 billion, confirming days of leaked details on the companies’ negotiations.
Those earliest reports began swirling on Sept. 24, the day Bloomberg published an article announcing Acceleron was in “advanced talks” for a buyout. The Wall Street Journal followed that news up days later with a report confirming Merck as the top bidder in those negotiations.
Rob Davis
On the heels of that reporting — and as the company’s stock was ticking up — Acceleron CEO Habib Dable reached out to Merck CEO Rob Davis on Sept. 28 to talk about “the market reaction to rumors regarding the proposed transaction,” according to Merck’s version of events, and asked Merck to up its offer of $180 per share. Davis declined to move on the price, and the partners signed the paperwork the following day.
It’s an odd bit of gamesmanship on Acceleron’s part and paints a picture that Acceleron looked to leverage leaked information to drive up its share price in anticipation of a deal. But in Acceleron’s telling of the story, a last-minute push from another potential partner could have perked the biotech’s ears on a potential bidding war. On Sept. 24, that suitor — dubbed “Party B” in the filing — reached out to Acceleron to express its interest in a buyout and discuss terms.
But just days later, on Sept. 28, the same day Dable asked Merck to up its offer, Party B backed out of the race, saying it “could not be competitive with the price that was speculated in the market and was unwilling to make the regulatory clearance commitment the Company’s financial advisors had indicated would be required,” Acceleron said.
That left Acceleron with Merck, a company with a new CEO and CSO looking to make a splash. Sotatercept could prove just the ticket as a potential blockbuster in the making with winning Phase II data in pulmonary arterial hypertension, or PAH, a rare CV disease.
Sunil Patel
Merck initially reached out to Acceleron in July to inquire about potential partnerships, but Dable made clear early that Acceleron wasn’t interested in out-licensing deals. Sunil Patel, Merck’s head of corporate development, locked down a meeting on July 19 during which he notified Acceleron that Merck planned to submit an offer of $160 per share to buy the biotech outright.
There was only one other company in the mix — “Party A,” or Bristol Myers Squibb. Bristol Myers turned down discussions on an acquisition but did propose another arrangement with Acceleron, which it partnered with on both sotatercept and anemia drug Reblozyl. The drug giant offered to waive all royalty rights Acceleron would owe if sotatercept was approved in return for waiving its own royalty rights to Reblozyl sales.
Acceleron mulled the offer over before determining “that the proposal, taking into account the significant tax obligation it would create, would not deliver value to the Company, increased the risk profile of the Company by reducing the diversification of its revenue opportunities and was not in the best interests of stockholders.”
Recent AMRN News
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
FEATURED Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • Sep 4, 2024 9:02 AM
FEATURED Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • Sep 4, 2024 8:45 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM